Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 CAR-NK Cells for Relapsed/Refractory Autoimmune Diseases
NCT06464679Phase 1Recruiting
- Sponsor
- Changhai Hospital
- Start
- Jun 2024
- Primary completion
- Dec 2025
- Modality
- CAR-T Cells, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD19 CAR NK cells in Sjogren's syndrome, systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM) and 1 more, sponsored by Changhai Hospital. Primary endpoints: Incidence of Dose-Limiting Toxicity at 48 weeks and Incidence of Treatment Emergent Adverse Events at 48 weeks. Started Jun 2024; status: recruiting.
02
Drugs
CD19 CAR NK cells
03
Conditions
Sjogren's syndromesystemic sclerosis (SSc)idiopathic inflammatory myopathy (IIM)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06464679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06464679.